@article{3053525,
    title = "Fibrinolytic/hemostatic variables in arterial hypertension: Response to
treatment with irbesartan or atenolol",
    author = "Makris, TK and Stavroulakis, GA and Krespi, PG and Hatzizacharias, AN and and Triposkiadis, FK and Tsoukala, CG and Votteas, VV and Kyriakidis, MK",
    journal = "American Journal of Hypertension",
    year = "2000",
    volume = "13",
    number = "7",
    pages = "783-788",
    publisher = "Oxford University Press",
    issn = "0895-7061, 1941-7225",
    doi = "10.1016/S0895-7061(00)00262-4",
    keywords = "irbesartan; atenolol; hemostasis; endothelial dysfunction; hypertension",
    abstract = "Essential hypertension is often accompanied by abnormalities of the
coagulation/fibrinolytic system, predisposing to a procoagulant state.
The aim of the present study was to compare the effects of atenolol
(beta(1)-blocker agent) and irbesartan (angiotensin II type 1 receptor
antagonist) on plasma levels of hemostatic/fibrinolytic and endothelial
function markers in a cohort of previously untreated hypertensives.
Fifty-four patients were randomly assigned to atenolol 25 to 150 mg (26
patients) or irbesartan 75 to 300 mg (28 patients). The plasma levels of
plasminogen activator inhibitor-1 antigen, thrombomodulin, tissue factor
pathway inhibitor antigen, fibrinogen, and factor XII were determined
before and after 6 months of therapy. Age, gender distribution, body
mass index, lipid profile, and baseline values of the measured markers
were similar in both groups. Baseline values for systolic and diastolic
blood pressure, as well as the reduction after treatment, were not
significantly different between the two groups. Treatment with
irbesartan was associated with a significant decrease in the levels of
all the parameters. Similar findings were observed in the atenolol
group, except for factor XII and tissue factor pathway inhibitor levels,
which were not significantly decreased in this group. The reduction,
however, of fibrinogen, plasminogen activator inhibitor-1, and
thrombomodulin was significantly greater in the irbesartan than in the
atenolol group. In conclusion, the results indicated that, despite an
equally controlled blood pressure, 6-month therapy with irbesartan was
associated with a more favorable modification of hemostatic/fibrinolytic
status than atenolol. (C) 2000 American Journal of Hypertension, Ltd."
}